Deerfield Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Deerfield Management’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-356,952	Closed	-$1.27M	–	108
2019 Q1	$1.27M	Buy	356,952 +290,172	+435%	+$1.57M	0.05%	91
2018 Q4	$265K	Sell	66,780 -395,592	-86%	-$5.06M	0.01%	98
2018 Q3	$9.13M	Sell	462,372 -336,789	-42%	-$8.51M	0.33%	71
2018 Q2	$25.4M	Buy	799,161 +173,592	+28%	+$6.25M	0.89%	46
2018 Q1	$23.1M	Buy	+625,569	New	+$41.1M	0.8%	50

Other funds holding MLNT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Deerfield Management's MLNT Position: Q2 2019 in Review

Deerfield Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q2 2019, closing a stake of 356,952 shares — an estimated $1.27M sold.

Deerfield Management first reported a position in MLNT in Q1 2018 and held it in 5 quarters. The position peaked at $25.4M in Q2 2018. 53 funds tracked by Wall St. Rank hold MLNT as of Q2 2019.

Deerfield Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Deerfield Management sold 356,952 Melinta Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $1.27M.
Deerfield Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q1 2018 and held it in 5 quarters.
Deerfield Management's Melinta Therapeutics, Inc. Common Stock position peaked at $25.4M in Q2 2018.
53 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Deerfield Management's 13F filing for Q2 2019, filed 14 Aug 2019.